Tirzepatide is a novel dual GIP and GLP-1 receptor agonist used for the treatment of type 2 diabetes and obesity.
Tirzepatide is ideal for individuals with type 2 diabetes seeking to improve glycemic control, as well as for those aiming for weight management and reduction.
Often initiated at 0.25 mg once weekly, gradually increased to a maintenance dose of 0.5 mg 0,75 mg and 1 mg once weekly.
